Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share, according to a press release issued Oct. 15, 2026.

The Salt Lake City-based clinical-stage company expects to receive gross proceeds of approximately $200 million before underwriting discounts, commissions, and estimated offering expenses. All shares are being sold by Recursion. The offering was expected to close on or about Oct. 16, 2026, subject to customary closing conditions.

Participating investors in the offering include Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management, among other institutional and healthcare-focused funds.

Leerink Partners, Goldman Sachs & Co., Morgan Stanley & Co., and Evercore Group are serving as joint bookrunning managers. Needham & Company is acting as lead manager.

The shares are being offered under a registration statement on Form S-3 that became automatically effective upon filing with the U.S. Securities and Exchange Commission on Feb. 12, 2025.